Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-acting isosorbide mononitrate

A Prakash1, A Markham

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|February 10, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Computer-aided detection thresholds can guide repeat rapid molecular testing in TB screening.

IJTLD open·2026
Same author

Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to <i>KRAS</i> mutational status.

ESMO gastrointestinal oncology·2026
Same author

Search for B^{0}→K^{*0}τ^{+}τ^{-} Decays at the Belle II Experiment.

Physical review letters·2025
Same author

Search for a Dark Higgs Boson Produced in Association with Inelastic Dark Matter at the Belle II Experiment.

Physical review letters·2025
Same author

Uncovering PD-L1 among immune cell predictive biomarkers and actionable genetic alterations in anal squamous-cell carcinomas in the era of immunotherapy.

ESMO open·2025
Same author

NK cell line modified to express a potent, DR5 specific variant of TRAIL, show enhanced cytotoxicity in ovarian cancer models.

Heliyon·2024
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Elantan long (EL), a novel isosorbide mononitrate formulation, offers sustained angina relief for up to 17 hours with once-daily dosing. This improved quality of life and efficacy without developing tolerance or rebound effects.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Elantan long (EL) is a unique controlled-release formulation of isosorbide mononitrate.
  • It delivers 30% of the dose immediately and the remaining 70% gradually over time.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of once-daily Elantan long (EL) in managing angina.

Main Methods:

  • Compared once-daily isosorbide mononitrate EL (50-100mg) with conventional isosorbide mononitrate/dinitrate and sustained-release nifedipine.
  • Assessed antianginal effects and quality-of-life indices.
  • Monitored for tolerance and rebound effects after 13 months of administration.

Main Results:

  • Once-daily EL demonstrated antianginal effects comparable to multiple daily doses of conventional nitrates and sustained-release nifedipine.

Related Experiment Videos

  • EL showed superior improvements in quality-of-life indices compared to conventional nitrate regimens.
  • No tolerance developed after prolonged use, and no rebound ischemia was observed upon discontinuation.

    • Conclusions:

    • Once-daily Elantan long (EL) provides effective and sustained antianginal therapy with improved quality of life.
    • Its favorable tolerability profile and lack of rebound effects make it a valuable treatment option for angina management.